Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors

被引:81
作者
Geiger, J [1 ]
Hönig-Liedl, P [1 ]
Schanzenbächer, P [1 ]
Walter, U [1 ]
机构
[1] Univ Wurzburg, Med Klin, Inst Klin Biochem & Pathobiochem, D-97080 Wurzburg, Germany
关键词
ADP derivative; thienopyridine; Ca2+; G-protein; purinoceptor;
D O I
10.1016/S0014-2999(98)00305-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human platelets express adenosine 5'-diphosphate (ADP)-specific purinoceptors of the P-2X and P-2Y receptor superfamily, but their structure, diversity, and precise pharmacological profile is not well understood. Here, functional assays with intact platelets and well-characterized nucleotide derivatives were performed in order to characterize the ligand specificity of these platelet-specific purinoceptors. For the signalling pathways investigated (aggregation, rapid Ca2+-influx, desensitization of Ca2+-influx, Ca2+-mobilization, inhibition of adenylyl cyclase), significant differences in ligand specificity were demonstrated. ADP activated all purinoceptors of human platelets, while adenosine 5'-triphosphate (ATP) was a weak agonist for the P-2X receptor and an antagonist for the P-2Y receptors, The ADP-receptor pathway-antagonist ticlopidine inhibited ADP-evoked aggregation and adenylyl cyclase inhibition but did not affect platelet purinoceptors associated with Ca2+-influx and Ca2+-mobilization. These results indicate the presence of three distinct ADP-selective purinoceptors on human platelets. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:235 / 246
页数:12
相关论文
共 35 条
  • [11] A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
    Gent, M
    Beaumont, D
    Blanchard, J
    Bousser, MG
    Coffman, J
    Easton, JD
    Hampton, JR
    Harker, LA
    Janzon, L
    Kusmierek, JJE
    Panak, E
    Roberts, RS
    Shannon, JS
    Sicurella, J
    Tognoni, G
    Topol, EJ
    Verstraete, M
    Warlow, C
    [J]. LANCET, 1996, 348 (9038) : 1329 - 1339
  • [12] PHOSPHORYLATION OF FOCAL ADHESION VASODILATOR-STIMULATED PHOSPHOPROTEIN AT SER157 IN INTACT HUMAN PLATELETS CORRELATES WITH FIBRINOGEN RECEPTOR INHIBITION
    HORSTRUP, K
    JABLONKA, B
    HONIGLIEDL, P
    JUST, M
    KOCHSIEK, K
    WALTER, U
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1994, 225 (01): : 21 - 27
  • [13] RECEPTORS FOR ADP ON HUMAN BLOOD-PLATELETS
    HOURANI, SMO
    HALL, DA
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (04) : 103 - 108
  • [14] Molecular basis for ADP-induced platelet activation II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets
    Jin, JG
    Daniel, JL
    Kunapuli, SP
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (04) : 2030 - 2034
  • [15] HOW SHOULD P-2X PURINOCEPTORS BE CLASSIFIED PHARMACOLOGICALLY
    KENNEDY, C
    LEFF, P
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1995, 16 (05) : 168 - 174
  • [16] Koesling D, 1997, HANDB EXP PHARM, V126, P181
  • [17] Activation of receptor-operated cation channels via P-2X1 not P-2T purinoceptors in human platelets
    MacKenzie, AB
    MahautSmith, MP
    Sage, SO
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (06) : 2879 - 2881
  • [18] MAHAUTSMITH MP, 1992, J BIOL CHEM, V267, P3060
  • [19] Elective coronary implantation of a new stent without conventional anticoagulation
    Markert, T
    Bertsch, C
    Langenfeld, H
    Schanzenbacher, P
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1996, 121 (40) : 1213 - 1219
  • [20] Michel AD, 1997, MOL PHARMACOL, V51, P524